ReviewThe American journal of case reports2025
Incidental High-Grade Sellar Solitary Fibrous Tumor Mimicking Non-Functioning Pituitary Adenoma: A Case Report and Literature Review.
Review in The American journal of case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Sellar Solitary Fibrous Tumor Mimicking Pituitary Adenoma: Diagnostic Pitfalls, Contemporary Pathological Classification, and Management Considerations.Diagnostics (Basel, Switzerland) · 2026Article
- Case Report: Sellar hemangioblastoma mimicking a pituitary macroadenoma: a diagnostic and surgical pitfall.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Sellar solitary fibrous tumors (SFT) are uncommon brain tumors belonging to the fibroblastic and myofibroblastic category of the 2021 World Health Organization (WHO) Classification of Central Nervous System (CNS) Tumors. Twenty-two instances of sellar WHO grade II and III SFT (SFT II/III) have been reported since 1983. SFTs II/III clinical and imaging findings resemble non-functioning pituitary adenomas (NFPAs). We report a 62-year-old woman with encephalopathy and an incidental WHO grade III sellar SFT presenting as a non-functioning pituitary mass. CASE REPORT A 62-year-old woman with encephalopathy and urosepsis was transferred for evaluation of an incidentally detected sellar mass. An endocrine workup was unremarkable and a presumed diagnosis of NFPA was made. A partial adenectomy was then performed through a trans-nasal trans-sphenoidal approach. Pathological analysis revealed a mesenchymal neoplasm with haphazardly arranged spindled to epithelioid cells, collagenized background, tortuous vasculature, high mitotic index, and Signal Transducer and Activator of Transcription 6 (STAT6) positivity. According to the 2016 CNS WHO guidelines, the diagnosis was an anaplastic hemangiopericytoma WHO grade III, now termed an SFT under the 2021 CNS WHO guidelines. Proton therapy to the dose of 59.4 gray given in 33 fractions was implemented adjuvantly. The residual tumor demonstrated shrinkage 1.5 years after proton therapy, and absence of recurrent disease after 3 years. CONCLUSIONS Sellar SFTs II/III can present as incidentalomas and be considered in the differential diagnosis of sellar masses. While some cause symptoms by local expansion mimicking NFPA presentations, local invasion and metastasis are reported. Surgical excision and pathologic confirmation guide management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.